Search
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … [L28026] On December 23, 2020, Health Canada issued an expedited authorization for the Moderna COVID-19 Vaccine.
Goserelin
go.drugbank.com/drugs/DB00014ApprovedInvestigationalIn men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. … In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state.
Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalIt is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling. … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be
Categories: Calcium Channels, N-Type, Complex MixturesSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … arthritis (RA) in combination with methotrexate.
Products: KEVZARA Solution for Injection in Pre-filled Pen 150mg, KEVZARA Solution for Injection in Pre-filled Pen 200mgMethyclothiazide
go.drugbank.com/drugs/DB00232ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … chemotherapy-induced neutropenia, including FN.
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … of an adjuvant.
Primidone
go.drugbank.com/drugs/DB00794ApprovedVet approved[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.